drugset / Trial / NCT05391048

An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition

NCT05391048

Phase 1 Completed 36 enrolled Impact Therapeutics, Inc.
RandomizedCrossoverOpen-labelOther

Summary

An open-label, randomized, single-dose, two-way crossover bioequivalence study to compare two strengths (10 mg and 20 mg) of IMP4297 capsules in healthy Chinese subjects under fed condition

Timeline

Start
2022-06-06
Primary completion
2022-07-21
Completion
2022-07-21

Drugs

EvaluationDrugModalityDoseRoute
Subject IMP4297 Unknown 10 mg Oral
Subject IMP4297 Unknown 20 mg Oral

Indications